Indo Borax acquires 64.26% of Kronox, triggers offer

Deal overview: Indo Borax becomes majority shareholder

Indo Borax & Chemicals Ltd has completed the acquisition of a 64.26% stake in Kronox Lab Sciences Ltd, making it the majority shareholder in the Vadodara-headquartered specialty chemicals company. The company said the acquisition of 2,38,44,000 equity shares was finalised on September 29, 2026. The shares represent 64.26% of Kronox Lab Sciences’ total paid-up equity share capital. The transaction value for this promoter stake purchase is ₹246.12 crore, as disclosed in filings and related reports.

The acquisition is positioned as Indo Borax’s largest strategic expansion to date, with a stated aim of product diversification. The companies involved have described Kronox as operating in high-purity excipients, reagents, and APIs. Indo Borax, as the purchaser, had entered into the Share Purchase Agreement (SPA) earlier, and the completion confirms that control has shifted to the acquirer. Alongside Indo Borax, Zenrock Chemicals Private Limited is involved as a person acting in concert (PAC) for the broader acquisition and open offer process.

What was acquired: shares, stake and pricing

The SPA, approved by Indo Borax’s Board on August 20, 2026, covered the purchase of 2,38,44,000 equity shares of face value ₹10 each in Kronox Lab Sciences. The agreed price cited in the disclosures is ₹103.22 per share. The aggregate consideration for the promoter share purchase is reported at ₹246.12 crore, with one filing also specifying ₹246,11,77,680.

This makes Indo Borax the controlling shareholder in Kronox Lab Sciences. The deal was structured as a cash consideration transaction. The sellers were identified as Kronox Lab Sciences’ promoters: Ketan Vinodchandra Ramani, Pritesh Vinodchandra Ramani, and Jogindersingh Gianchand Jaswal. Indo Borax’s move brings a clear change in ownership and control, and it also triggers the mandatory open offer obligations under the SEBI (SAST) framework.

Mandatory open offer: up to 25.79% additional stake

Following the change in control, Indo Borax & Chemicals Limited has published the Detailed Public Statement (DPS) for a mandatory open offer. The open offer, along with PAC Zenrock Chemicals, is to acquire up to 95,70,000 equity shares. This represents 25.79% of Kronox Lab Sciences’ voting share capital.

The offer price for public shareholders has been set at ₹157.27 per equity share, as stated in the DPS. The maximum consideration has been stated as ₹150.5 crore if the offer is fully accepted. The offer price has been described as determined in accordance with SAST regulations.

Key dates: acquisition and open offer timeline

Indo Borax’s timeline includes three distinct steps: agreement, funding, and closing. The SPA was entered into on August 20, 2026, when the Board also approved the acquisition plan. Funding to support the acquisition was availed on September 23, 2026. The company then confirmed completion of the promoter stake acquisition on September 29, 2026.

On the open offer process, the DPS outlines the operational schedule for shareholders. The last date for dispatch of the Letter of Offer to public shareholders is October 8, 2026. The tendering period is scheduled to open on October 15, 2026, and close on October 29, 2026. Indo Borax must communicate acceptance or rejection of tendered shares by November 13, 2026.

Financing: from debt-free to a new ₹225 crore facility

To finance the acquisition, Indo Borax has moved away from its debt-free status by availing a new debt facility. The company disclosed it secured ₹225 crore funding from a lending institution, with the funding availed on September 23, 2026. The stated purpose of the facility is the acquisition of equity shares of Kronox Lab Sciences Limited.

The disclosures also indicate the company will make further updates as required under SEBI regulations. The funding step is material because it bridges the cash requirement for the transaction and formalises Indo Borax’s capital structure shift in connection with the acquisition. While the acquisition consideration is ₹246.12 crore, the disclosed funding facility is ₹225 crore, indicating that the acquisition funding includes this borrowing as a major component.

Why Kronox: diversification into specialty chemicals applications

Indo Borax has framed the acquisition as a strategic expansion intended to diversify products. Kronox Lab Sciences is described as a specialty chemicals player with a focus on high-purity excipients, reagents, and APIs. This positioning matters because these segments typically require consistent quality specifications and can be closely tied to regulated downstream industries.

The deal therefore represents more than a financial investment and is being presented as an operating expansion into adjacent product categories. Still, the disclosures focus on the transaction mechanics and compliance steps rather than projecting future operating outcomes. Investors will likely track how Indo Borax integrates Kronox and whether the open offer materially changes the post-offer shareholding structure.

Market snapshot: stock reaction and disclosure trail

A market report around the August 20, 2026 announcement noted Indo Borax’s shares were up 7.44% after the Board approved the acquisition. The transaction has since progressed through the SPA, funding, and completion milestones with multiple disclosures.

Separately, the open offer documentation provides a clearer view of the potential total stake buildup. Indo Borax has already acquired 64.26%. If the open offer for 25.79% is fully tendered, the acquirer group could increase its holding further, subject to the offer process and shareholder participation.

Key numbers at a glance

Market impact: what changes for investors and shareholders

For Kronox Lab Sciences shareholders, the most immediate event is the open offer window and the stated offer price of ₹157.27 per share. The timeline from October 15 to October 29, 2026 provides the period during which eligible shareholders can tender shares, subject to the terms in the Letter of Offer.

For Indo Borax investors, the notable change is the transition to a leveraged funding structure for the transaction. The company has disclosed availing ₹225 crore debt to fund the acquisition, moving away from a debt-free status. The market also reacted at the announcement stage, with a 7.44% move cited around the Board approval date. Further market interpretation will depend on post-acquisition disclosures and any updates related to SEBI compliance, the open offer outcome, and integration milestones.

Analysis: what the structure signals

The structure combines a controlling stake purchase via SPA and a mandatory open offer under takeover regulations. This is a common route for change-of-control transactions in listed companies, allowing the acquirer to secure control first and then provide an exit opportunity to public shareholders at a disclosed offer price.

Another signal is the sequencing of funding. Indo Borax’s disclosure of ₹225 crore funding ahead of completion indicates the company sought to lock in financing capacity before closing, reducing execution risk. The difference between the acquisition consideration (₹246.12 crore) and the debt facility (₹225 crore) also underlines that the transaction funding mix is not fully described in the provided details beyond the disclosed facility.

Conclusion: next milestones are in October and November

Indo Borax’s acquisition of 64.26% in Kronox Lab Sciences for ₹246.12 crore is now complete, and the company has also put in place a ₹225 crore funding facility linked to the transaction. The next key milestones are tied to the mandatory open offer process. The Letter of Offer is scheduled for dispatch by October 8, 2026, followed by the tendering window from October 15 to October 29, 2026. The company is required to communicate acceptance or rejection of tendered shares by November 13, 2026, keeping investor focus on the open offer’s final participation and resulting shareholding.